Скачать или смотреть PGEN Decision Looms as Controversy Erupts Between Trump & FDA

PGEN Decision Looms as Controversy Erupts Between Trump & FDA

The FDA is facing chaos just weeks before a critical decision on Precigen’s groundbreaking therapy. Political pressure is mounting as Donald Trump pushes back on the agency’s recent actions, and top regulator Vinay Prasad abruptly resigns. This video breaks down what’s happening behind the scenes — and what it could mean for PGEN’s fate.

I use Interactive Brokers to buy most of the stocks I talk about. Create an account and get FREE stocks here: https://ibkr.com/referral/olivier574

Disclaimer
This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong.

Tags
Precigen, PGEN stock, PGEN, Precigen PRGN2012, PGEN FDA approval, PGEN news, PGEN share price, Precigen stock analysis, PDUFA August 27 2025, FDA approval catalyst, biotech stock catalyst, PRGN2012 approval date, biotech stocks to watch, gene therapy FDA approval, FDA decision 2025, PRGN2012, recurrent respiratory papillomatosis treatment, RRP gene therapy, Precigen gene therapy, FDA gene therapy approval, EVERSANA commercialization, Randal Kirk, Phil Tennant Precigen, Vinay Prasad FDA, Roger Song Jefferies, biotech investing 2025, high potential biotech stocks, small cap biotech stocks, PGEN short squeeze, biotech takeover target, biotech M&A rumors, PRGN-2012 BLA submission, PGEN Phase 2 trial results, biotech FDA calendar 2025, top FDA approvals 2025, biotech penny stocks, undervalued biotech stocks, August 2025 biotech catalysts, PGEN long term potential, FDA priority review 2025, rare disease FDA approval, breakthrough therapy designation, Precigen UltraCAR-T, UltraPorator technology, non-viral CAR-T therapy, biotech insider ownership, billionaires buying biotech, PGEN hedge fund interest, PGEN institutional ownership, FDA fast track approval, PGEN earnings 2025, top biotech buyout targets 2025, vinay prasad leaves FDA, vinay prasad FDA, trump prasad,